Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $10.00 price target on the stock. A number of other analysts have also weighed in on KPTI. Robert W. Baird reduced their price target on shares of […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 12,550,000 shares, a decline of 24.0% from the June 15th total of 16,520,000 shares. Based on an average daily trading volume, of 2,890,000 shares, the days-to-cover […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 12,550,000 shares, a drop of 24.0% from the June 15th total of 16,520,000 shares. Based on an average trading volume of 2,890,000 shares, the days-to-cover ratio […]